18:01 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Patient sample and mouse studies suggest agonizing FFAR1 could help treat temporal lobe epilepsy. In postmortem brain tissue samples from patients with temporal lobe epilepsy, neocortical levels of FFAR1 protein were higher than...
18:18 , Apr 13, 2018 |  BC Week In Review  |  Company News

Tasly gets Chinese rights to Lilly's diabetes candidate

Eli Lilly and Co. (NYSE:LLY) granted the Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. subsidiary of Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) exclusive rights to develop and commercialize LY-2922470 in China, including Hong Kong, Macao and Taiwan....
23:34 , Sep 14, 2017 |  BC Innovations  |  Strategy

Numerate’s Intelligence

With three new partnerships formed since June, Numerate Inc. is picking up steam and demonstrating that industry and academic groups alike are finding utility in its AI platform, which can build robust predictive models for...
18:15 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro , cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...
07:00 , Oct 13, 2014 |  BioCentury  |  Strategy

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
07:00 , Aug 14, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes G protein-coupled receptor 120 (GPR120; O3FAR1) Cell culture and mouse studies have identified a GPR120 agonist that could be used to treat type...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

Fasiglifam: Development discontinued

On Dec. 26, 2013, Takeda said it is discontinuing development of fasiglifam due to concerns about liver safety. The compound was in Phase III testing for Type II diabetes. The pharma said it concluded that...
23:23 , Dec 27, 2013 |  BC Extra  |  Top Story

Takeda off after dropping fasiglifam

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) lost Y209.3 billion ($2 billion) in market cap on Friday after discontinuing development of fasiglifam ( TAK-875 ) due to concerns about liver safety. The free fatty acid receptor 1...
01:06 , Dec 27, 2013 |  BC Extra  |  Company News

Takeda drops diabetes compound fasiglifam

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it is discontinuing development of fasiglifam ( TAK-875 ) due to concerns about liver safety. The free fatty acid receptor 1 ( FFAR1 ; GPR40 ) agonist was in...